Human FGFR1 / CD331 Protein, His Tag (SPR verified)
分子別名(Synonym)
FGFR1,BFGFR,CD331,CEK,FGFBR,FLG,HBGFR,N-SAM,FLT2,H2,KAL2,FLJ14326
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human FGF R1, His Tag (FG1-H5223) is expressed from human 293 cells (HEK293). It contains AA Arg 22 - Ile 376 (Accession # P11362-7).
Predicted N-terminus: Arg 22
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 41.2 kDa. The protein migrates as 60-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
成纖維細(xì)胞生長因子受體1(FGFR1)也稱為堿性成纖維細(xì)胞增長因子受體1,FMS樣酪氨酸激酶,CD331,是一種受體酪氨酸激酶,其配體是成纖維細(xì)胞成長因子家族的特定成員。這種蛋白質(zhì)是幾種成纖維細(xì)胞生長因子受體之一,這些受體是參與細(xì)胞分裂、細(xì)胞生長和成熟調(diào)節(jié)、血管形成、傷口愈合和胚胎發(fā)育等重要過程的相關(guān)蛋白質(zhì)。FGFR1蛋白橫跨細(xì)胞膜,因此蛋白的一端留在細(xì)胞內(nèi),另一端從細(xì)胞外表面伸出。這種定位允許FGFR1蛋白與細(xì)胞外的特定生長因子相互作用,并接收有助于細(xì)胞對(duì)其環(huán)境作出反應(yīng)的信號(hào)。當(dāng)生長因子附著在FGFR1蛋白上時(shí),受體會(huì)在細(xì)胞內(nèi)引發(fā)一系列化學(xué)反應(yīng),指示細(xì)胞發(fā)生某些變化,例如成熟以承擔(dān)特定的功能。FGFR1蛋白被認(rèn)為在神經(jīng)系統(tǒng)的發(fā)育中起著重要作用。這種蛋白質(zhì)也可能有助于調(diào)節(jié)長骨的生長,如手臂和腿部的大骨頭。
關(guān)鍵字: FGFR1;FGFR1蛋白;FGFR1重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。